QQQ   439.18 (-1.09%)
AAPL   170.66 (-2.54%)
MSFT   407.18 (-1.87%)
META   495.24 (-0.59%)
GOOGL   132.22 (-0.85%)
AMZN   175.68 (-1.07%)
TSLA   183.03 (-2.72%)
NVDA   855.58 (+0.38%)
NIO   5.28 (-0.94%)
AMD   202.38 (-1.45%)
BABA   71.92 (-0.11%)
T   17.17 (+2.20%)
F   12.72 (-0.16%)
MU   95.25 (-0.54%)
CGC   2.91 (-3.64%)
GE   161.72 (+0.44%)
DIS   113.60 (-0.08%)
AMC   4.32 (+0.00%)
PFE   25.75 (-0.54%)
PYPL   60.73 (+1.25%)
XOM   105.06 (+0.67%)
QQQ   439.18 (-1.09%)
AAPL   170.66 (-2.54%)
MSFT   407.18 (-1.87%)
META   495.24 (-0.59%)
GOOGL   132.22 (-0.85%)
AMZN   175.68 (-1.07%)
TSLA   183.03 (-2.72%)
NVDA   855.58 (+0.38%)
NIO   5.28 (-0.94%)
AMD   202.38 (-1.45%)
BABA   71.92 (-0.11%)
T   17.17 (+2.20%)
F   12.72 (-0.16%)
MU   95.25 (-0.54%)
CGC   2.91 (-3.64%)
GE   161.72 (+0.44%)
DIS   113.60 (-0.08%)
AMC   4.32 (+0.00%)
PFE   25.75 (-0.54%)
PYPL   60.73 (+1.25%)
XOM   105.06 (+0.67%)
QQQ   439.18 (-1.09%)
AAPL   170.66 (-2.54%)
MSFT   407.18 (-1.87%)
META   495.24 (-0.59%)
GOOGL   132.22 (-0.85%)
AMZN   175.68 (-1.07%)
TSLA   183.03 (-2.72%)
NVDA   855.58 (+0.38%)
NIO   5.28 (-0.94%)
AMD   202.38 (-1.45%)
BABA   71.92 (-0.11%)
T   17.17 (+2.20%)
F   12.72 (-0.16%)
MU   95.25 (-0.54%)
CGC   2.91 (-3.64%)
GE   161.72 (+0.44%)
DIS   113.60 (-0.08%)
AMC   4.32 (+0.00%)
PFE   25.75 (-0.54%)
PYPL   60.73 (+1.25%)
XOM   105.06 (+0.67%)
QQQ   439.18 (-1.09%)
AAPL   170.66 (-2.54%)
MSFT   407.18 (-1.87%)
META   495.24 (-0.59%)
GOOGL   132.22 (-0.85%)
AMZN   175.68 (-1.07%)
TSLA   183.03 (-2.72%)
NVDA   855.58 (+0.38%)
NIO   5.28 (-0.94%)
AMD   202.38 (-1.45%)
BABA   71.92 (-0.11%)
T   17.17 (+2.20%)
F   12.72 (-0.16%)
MU   95.25 (-0.54%)
CGC   2.91 (-3.64%)
GE   161.72 (+0.44%)
DIS   113.60 (-0.08%)
AMC   4.32 (+0.00%)
PFE   25.75 (-0.54%)
PYPL   60.73 (+1.25%)
XOM   105.06 (+0.67%)
NYSE:CRL

Charles River Laboratories International (CRL) Stock Price, News & Analysis

$259.03
+0.11 (+0.04%)
(As of 09:40 AM ET)
Today's Range
$256.27
$259.04
50-Day Range
$203.52
$264.67
52-Week Range
$161.65
$265.80
Volume
9,780 shs
Average Volume
597,286 shs
Market Capitalization
$13.29 billion
P/E Ratio
28.12
Dividend Yield
N/A
Price Target
$246.54

Charles River Laboratories International MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.55 Rating Score
Upside/​Downside
4.2% Downside
$246.54 Price Target
Short Interest
Healthy
3.82% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
0.95mentions of Charles River Laboratories International in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$3.69 M Sold Last Quarter
Proj. Earnings Growth
12.59%
From $11.04 to $12.43 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.60 out of 5 stars

Medical Sector

90th out of 960 stocks

Commercial Physical Research Industry

4th out of 13 stocks


CRL stock logo

About Charles River Laboratories International Stock (NYSE:CRL)

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

CRL Stock Price History

CRL Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Detecting Cancer in Mere Seconds: Early Investment Opportunity
A revolutionary cancer diagnostic tool is likely to come to fruition with anticipated FDA approval expected in just months. With the ability to detect cancer's "molecular fingerprint" in just seconds, it also offers far superior accuracy to current detection methods and reduces the need for invasive biopsies.
Charles River Teams Up With Pluristyx For Stem Cell Research
Ten Big Losers To Start The Year. Tesla Isn't The Worst.
10 Narrow Moat Stocks Hedge Funds Are Buying
Charles River Leaps on CASGEVY News
See More Headlines
Receive CRL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
3/05/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
Life Sciences Tools & Services
CUSIP
15986410
Employees
21,800
Year Founded
1947

Price Target and Rating

Average Stock Price Target
$246.54
High Stock Price Target
$290.00
Low Stock Price Target
$203.00
Potential Upside/Downside
-4.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.55
Research Coverage
11 Analysts

Profitability

Net Income
$474.62 million
Pretax Margin
14.08%

Debt

Sales & Book Value

Annual Sales
$4.13 billion
Cash Flow
$16.46 per share
Book Value
$70.15 per share

Miscellaneous

Free Float
50,633,000
Market Cap
$13.28 billion
Optionable
Optionable
Beta
1.39

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report














CRL Stock Analysis - Frequently Asked Questions

Should I buy or sell Charles River Laboratories International stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories International in the last year. There are currently 5 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CRL shares.
View CRL analyst ratings
or view top-rated stocks.

What is Charles River Laboratories International's stock price target for 2024?

11 equities research analysts have issued twelve-month price objectives for Charles River Laboratories International's shares. Their CRL share price targets range from $203.00 to $290.00. On average, they predict the company's stock price to reach $246.54 in the next twelve months. This suggests that the stock has a possible downside of 4.2%.
View analysts price targets for CRL
or view top-rated stocks among Wall Street analysts.

How have CRL shares performed in 2024?

Charles River Laboratories International's stock was trading at $236.40 at the beginning of the year. Since then, CRL stock has increased by 8.9% and is now trading at $257.48.
View the best growth stocks for 2024 here
.

Are investors shorting Charles River Laboratories International?

Charles River Laboratories International saw a increase in short interest in February. As of February 15th, there was short interest totaling 1,920,000 shares, an increase of 14.3% from the January 31st total of 1,680,000 shares. Based on an average daily volume of 536,100 shares, the short-interest ratio is presently 3.6 days. Approximately 3.8% of the company's stock are short sold.
View Charles River Laboratories International's Short Interest
.

When is Charles River Laboratories International's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CRL earnings forecast
.

How were Charles River Laboratories International's earnings last quarter?

Charles River Laboratories International, Inc. (NYSE:CRL) released its quarterly earnings results on Wednesday, February, 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.39 by $0.07. The medical research company earned $1.01 billion during the quarter, compared to analysts' expectations of $991.25 million. Charles River Laboratories International had a trailing twelve-month return on equity of 16.53% and a net margin of 11.49%. The company's revenue was down 7.9% on a year-over-year basis. During the same period last year, the company earned $2.98 EPS.
Read the conference call transcript
.

What guidance has Charles River Laboratories International issued on next quarter's earnings?

Charles River Laboratories International updated its FY 2024 earnings guidance on Wednesday, February, 14th. The company provided EPS guidance of 10.900-11.400 for the period, compared to the consensus earnings per share estimate of 10.790. The company issued revenue guidance of $4.2 billion-$4.3 billion, compared to the consensus revenue estimate of $4.2 billion.

What is James C. Foster's approval rating as Charles River Laboratories International's CEO?

291 employees have rated Charles River Laboratories International Chief Executive Officer James C. Foster on Glassdoor.com. James C. Foster has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Charles River Laboratories International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Charles River Laboratories International investors own include NVIDIA (NVDA), Boeing (BA), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA), Salesforce (CRM), Abbott Laboratories (ABT), Mastercard (MA), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

Who are Charles River Laboratories International's major shareholders?

Charles River Laboratories International's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.66%), Clearbridge Investments LLC (2.86%), Price T Rowe Associates Inc. MD (2.81%), Allspring Global Investments Holdings LLC (2.27%), Meritage Group LP (2.25%) and Mackenzie Financial Corp (1.79%). Insiders that own company stock include Birgit Girshick, David Ross Smith, Deborah Turner Kochevar, George Massaro, James C Foster, James C Foster, Joseph W Laplume, Michael Gunnar Knell, Richard F Wallman, Shannon M Parisotto, Victoria L Creamer, Victoria L Creamer, William D Barbo and William D Barbo.
View institutional ownership trends
.

How do I buy shares of Charles River Laboratories International?

Shares of CRL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Charles River Laboratories International have any subsidiaries?
The following companies are subsidiares of Charles River Laboratories International: 3313290 Nova Scotia Company, 9904140 Canada Inc., Accugenix Inc., Agilux Laboratories, Argenta Discovery 2009 Limited, Ballardvale C.V., Beijing Vital River Laboratory Animal Technology Co. Ltd., BioFocus DPI (Holdings) Ltd., Biological Laboratories Europe Ltd. ("BioLabs"), Blue Stream Laboratories, Brains On-Line, CRL Dutch Holding Company B.V., CRL Group France, CRL Group International France, CRL Holding Germany GmbH, CRL Holding Netherlands B.V., CRL Safety Assessment Inc., Celsis Group Limited, Celsis International, Celsis International B.V., Celsis International GmbH, Celsis International Limited, Celsis Limited, Cerebricon, Chantest, Charles River Detecção Microbiana e de Endotoxina Participações Ltda, Charles River Discovery Research Services Finland, Charles River Discovery Research Services Germany GmbH, Charles River Discovery Research Services Inc., Charles River Discovery Research Services International Inc., Charles River Discovery Research Services UK Limited, Charles River Endotoxin Microbial Detection Europe SAS, Charles River Endotoxin and Microbial Detection Israel, Charles River Endotoxin and Microbial Detection Singapore Pte. Ltd., Charles River Germany GmbH & Co. KG, Charles River Germany Verwaltungs GmbH, Charles River Holdings LLC, Charles River Laboratories Ashland LLC, Charles River Laboratories Asia Holdings Limited, Charles River Laboratories Australia Pty. Ltd., Charles River Laboratories Belgium SPRL, Charles River Laboratories Cleveland Inc., Charles River Laboratories Copenhagen, Charles River Laboratories Den Bosch B.V., Charles River Laboratories Edinburgh Ltd., Charles River Laboratories España SA, Charles River Laboratories Evreux, Charles River Laboratories France Safety Assessment SAS, Charles River Laboratories France-C.R.L.F. SAS, Charles River Laboratories Germany GmbH, Charles River Laboratories Group, Charles River Laboratories Holding Europe SAS, Charles River Laboratories Holding SAS, Charles River Laboratories Holdings Limited, Charles River Laboratories Hungary, Charles River Laboratories I Delaware Holdings Inc., Charles River Laboratories II Delaware Holdings Inc., Charles River Laboratories Inc., Charles River Laboratories India Private Limited, Charles River Laboratories Ireland Holding Unlimited Company, Charles River Laboratories Ireland Limited, Charles River Laboratories Italia Srl, Charles River Laboratories Japan Inc., Charles River Laboratories Korea, Charles River Laboratories Luxembourg S.a.r.l., Charles River Laboratories Montreal ULC, Charles River Laboratories Poland Sp. Z.o.o., Charles River Laboratories Research Models and Services Germany GmbH, Charles River Laboratories SA France Acquisition SAS, Charles River Laboratories SA France Holdings SAS, Charles River Laboratories SA Japan KK, Charles River Laboratories SA Netherlands Holdings B.V., Charles River Laboratories SA USA Inc., Charles River Laboratories Saint Nazaire, Charles River Laboratories Saint‑Constant S.A., Charles River Microbial Solutions Company (Shanghai) Limited, Charles River Microbial Solutions International Limited, Charles River Nederland B.V., Charles River UK Limited, Charles River ULC, CiToxLAB, Citox Inc., Citoxlab USA LLC, Cognate BioServices, Genetic Models, HemaCare, Inveresk Research, KWS BioTest, KWS BioTest Limited, MPI Research, Molecular Therapeutics, Nastor Investments, NewLab BioQuality AG, Northwest Kinetics, Oncotest, Pathology Associates International Corporation, Piedmont Research Center, Primedica, Retrogenix Limited, River Valley Farms, Saothorlanna Bitheolaiocha Idirnaisiunta Teoranta, Sierra Biomedical, Solvo Biotechnology USA Inc., Solvo Biotechnológiai Zrt, Springborn Laboratories, Sunrise Farms Inc., Systems Pathology Company LLC, Tektagen Inc, Vigene Biosciences Inc., WIL Research, Zhanjiang A&C Biological Ltd., and Zhejiang Vital River Laboratory Animal Technology Co. Ltd..
Read More
This page (NYSE:CRL) was last updated on 3/5/2024 by MarketBeat.com Staff